CHICAGO—A new approach to dealing simultaneously with several of the identified molecular processes taking place in cancer has brought new prospects for extending life in patients with advanced non small-call lung cancer who have already received chemotherapy. The American Society of Clinical Oncology annual meeting heard phase II study findings from patients treated with ganetespib — a drug which inhibits heat shock protein, known as a “molecular chaperone” because it controls the activity of a number of different cancer-causing molecular processes. Used second line in combination with docetaxel the drug produced marked and highly significant improvements in progression-free and overall survival. Dr Suresh Ramalingam from Emory University in Atlanta discussed the study findings with Peter Goodwin.
You may also like...
Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent 7 Feb, 2020 Audio Journal of Oncology with Oncology Times News from the 2013 European Cancer Congress 18 Oct, 2013 Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia 19 Dec, 2013 Audio Journal of Oncology in Advance – October 1st, 2006 1 Oct, 2006
- Previous story Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours
- Next story The WIN consortium meets in Paris – a boost for cancer science
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014